Search Results for: MBIO
Source: ThinkstockBiotech and emerging health care technology companies both fit into a high-stake poker match on Wall Street. Investors can earn exponential rewards if they are right, or they can...
Published:
Eleven Biotherapeutics was at the top of the list for gainers in the market Wednesday. This move comes on an update from the company’s most advanced study.
Published:
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.
Published:
Gossamer Bio shares dived on Tuesday after the company announced midstage results from its asthma and chronic rhinosinusitis studies.
Published:
MGIC Investment Corporation (NYSE: MTG) is one of the troubled mortgage insurers which we routinely worry about for both viability and relevance. This morning’s earnings report does nothing to...
Published:
Ambac Financial Group, Inc. (NYSE: ABK) has finally come clean, but this coming clean is so brutal that it will be dirty. Below are some of the summary changes, many of which are substantial: AMBAC...
Published:
Rite Aid Corporation (RAD) Ugly earnings. No turnaround here. Falls to $2.71 from 52-week high of $6.74. MBIA (MBI) Concerns about CDOs being insured here. Falls to $18.84 from 52-week high of...
Published:
iBio has provided an update on its COVID-19 vaccine manufacturing capacity and said that it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals.
Published:
Sesen Bio shares took a beating on Thursday despite posting positive data for its late-stage trial for patients with high-grade non-muscle invasive bladder cancer.
Published:
Last Updated:
Iovance Biotherapeutics is one of the early big winners from ASCO. The firm announced updates from ongoing clinical trials including new interim data from studies of patients with advanced cervical...
Published:
Last Updated:
Goldman Sachs issued an interesting note on the various bond insurers, although some of this data may have been put out yesterday. The firm is listing three scenario valuation assumptions for:...
Published:
Like all developmental drug companies, Bio-Path is betting on the success of its drug candidates. Drugs that are in trials often fail, so investors need to gamble that one or more of its treatments...
Published:
Eric Dinallo, New York State’s insurance regulator, is a clever devil. He has effectively pitted Warren Buffett against the nation’s biggest money center banks to see who will get the chance...
Published:
What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of shareholder value? That's what happened to Bio-Path.
Published: